Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC‐derived cardiomyocytes
Brian M. Necela, Bianca C. Axenfeld, Daniel Serie, et al.
Clinical and Translational Medicine (2017) Vol. 6, Iss. 1
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Targeting autophagy in obesity: from pathophysiology to management
Yingmei Zhang, James R. Sowers, Jun Ren
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 6, pp. 356-376
Closed Access | Times Cited: 303
Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer
Tomoya Kitani, Sang‐Ging Ong, Chi Keung Lam, et al.
Circulation (2019) Vol. 139, Iss. 21, pp. 2451-2465
Open Access | Times Cited: 167
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Rudolf A. de Boer, Jean‐Sébastien Hulot, Carlo G. Tocchetti, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 12, pp. 2272-2289
Open Access | Times Cited: 135
The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
Mengmeng Lin, Weiping Xiong, Shiyuan Wang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 8
Open Access | Times Cited: 42
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Holden Eaton, Kerstin N. Timm
Cardio-Oncology (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming
Huan Wang, Robert P. Sheehan, Adam C. Palmer, et al.
Cell Systems (2019) Vol. 8, Iss. 5, pp. 412-426.e7
Open Access | Times Cited: 61
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martı́n-Castillo, Sònia Pernas, Joan Dorca, et al.
Oncotarget (2018) Vol. 9, Iss. 86, pp. 35687-35704
Open Access | Times Cited: 60
Cell line-directed breast cancer research based on glucose metabolism status
Pegah Farhadi, Reza Yarani, Elahe Valipour, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112526-112526
Open Access | Times Cited: 48
Heart Failure With Targeted Cancer Therapies
Virginia S. Hahn, Kathleen W. Zhang, Lova Sun, et al.
Circulation Research (2021) Vol. 128, Iss. 10, pp. 1576-1593
Open Access | Times Cited: 45
Characterization of dysregulated lncRNA-mRNA network based on ceRNA hypothesis to reveal the occurrence and recurrence of myocardial infarction
Guangde Zhang, Haoran Sun, Yawei Zhang, et al.
Cell Death Discovery (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 50
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell
Nazish Sayed, Mohamed Ameen, Joseph C. Wu
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 949-959
Open Access | Times Cited: 45
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes
Alexandre J. S. Ribeiro, Brian D. Guth, Michael J. Engwall, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 44
Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
Anurag Choksey, Kerstin N. Timm
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 441-441
Open Access | Times Cited: 33
Anthracyclines induce cardiotoxicity through a shared gene expression response signature
E. Renee Matthews, Omar D. Johnson, K Horn, et al.
PLoS Genetics (2024) Vol. 20, Iss. 2, pp. e1011164-e1011164
Open Access | Times Cited: 5
The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
Michaela Poliaková, Daniel M. Aebersold, Yitzhak Zimmer, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 46
Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes
Yosuke Kurokawa, Michael R. Shang, Rose T. Yin, et al.
Toxicology Letters (2018) Vol. 285, pp. 74-80
Closed Access | Times Cited: 45
Clinical Trial in a Dish
Chi Keung Lam, Joseph C. Wu
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 41, Iss. 3, pp. 1019-1031
Open Access | Times Cited: 30
A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines
Weina Li, Xiaozhen Cheng, Guanghui Zhu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
Shima Moradi‐Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, et al.
Journal of Pharmacy and Pharmacology (2018) Vol. 70, Iss. 7, pp. 841-854
Open Access | Times Cited: 36
Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity
Mohit Kumar, Chellappagounder Thangavel, Richard C. Becker, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 86-86
Open Access | Times Cited: 31
Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies
Dilip Thomas, Sushma Shenoy, Nazish Sayed
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 26
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
Mattia Lunardi, Ahmed Al‐Habbaa, Mahmoud Abdelshafy, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Multicellular Human Cardiac Organoids Transcriptomically Model Distinct Tissue-Level Features of Adult Myocardium
Charles M. Kerr, Dylan Richards, Donald R. Menick, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8482-8482
Open Access | Times Cited: 23
Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy
Kalyan R. Chitturi, Ethan Burns, Ibrahim N. Muhsen, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 4, pp. 475-491
Closed Access | Times Cited: 15
hiPSCs in cardio-oncology: deciphering the genomics
Emily Pinheiro, K. Ashley Fetterman, Paul W. Burridge
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 935-948
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top